Boston’s Gelesis on Friday announced it’s raised $12 million in new funding to further develop a pill to treat the physiological symptoms of hunger.
The drug has the potential to treat overweight, obese, and diabetic patients, the company said.
The treatment, Gelesis100, offers an alternative to surgery and other invasive procedures, the firm said. It has so far gone through a series of clinical, preclinical, and in vitro studies, according to Gelesis.
Investors in the new round included Boston-based PureTech, which founded Gelesis in 2006, and the Pritzker/Vlock family office. Gelesis has now raised $42 million to date.
Kyle Alspach has worked in journalism in Massachusetts since 2005 and was one of the original staff writers at BetaBoston.
Follow Kyle on Twitter